EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

Journal of Clinical Investigation

Volumn 122, Issue 4, 2012, Pages 1487-1502

  White, Robert E ^a   Rämer, Patrick C ^b   Naresh, Kikkeri N ^c   Meixlsperger, Sonja ^b   Pinaud, Laurie ^a   Rooney, Cliona ^d   Savoldo, Barbara ^d   Coutinho, Rita ^e   Bödör, Csaba ^e   Gribben, John ^e   Ibrahim, Hazem A ^c   Bower, Mark ^f   Nourse, Jamie P ^g   Gandhi, Maher K ^g   Middeldorp, Jaap ^h   Cader, Fathima Z ⁱ   Murray, Paul ⁱ   Münz, Christian ^b   Allday, Martin J ^a,j  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR NUCLEAR ANTIGEN 3B; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER INVASION; CANCER SCREENING; CELL KILLING; CONTROLLED STUDY; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CHEMOKINE CXCL10; CHIMERA; DNA MUTATIONAL ANALYSIS; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE DELETION; GENES, TUMOR SUPPRESSOR; GENES, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-GAMMA; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MUTATION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS; TUMOR VIRUS INFECTIONS;

EID: 84859702791     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58092     Document Type: Article

References (56)

1. Young LS, Rickinson AB. Epstein-Barr virus:40 years on. Nat Rev Cancer. 2004;4(10):757-768.
2. Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epsteinbarr virus: an important vaccine target for cancer prevention. Sci Transl Med. 2011;3(107):107fs7.
3. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75-82. (Pubitemid 33741978)
4. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3(10):801-812. (Pubitemid 37328658)
5. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ. Extensive Co-Operation between the Epstein- Barr Virus EBNA3 Proteins in the Manipulation of Host Gene Expression and Epigenetic Chromatin Modification. PLoS ONE. 2010;5(11):e13979.
6. Hertle ML, et al. Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog. 2009; 5(7):e1000506.
7. Zhao B, et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A. 2011;108(1):337-342.
8. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene. 2008;27(4):421-433.
9. Vereide DT, Sugden B. Lymphomas differ in their dependence on Epstein-Barr virus. Blood. 2011;117(6):1977-1985.
10. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog. 2010;6(6):e1000951.
11. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A. 2011;108(5):1919-1924.
12. Allday M. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol. 2009;19(6):366-376.
13. Nikitin PA, et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe. 2010;8(6):510-522.
14. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein- Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol. 1992;66(5):2893-2903.
15. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44. (Pubitemid 40299772)
16. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
17. Murray RJ, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein- Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176(1):157-168.
18. Khanna R, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992;176(1):169-176.
19. Münz C, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein- Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191(10):1649-1660. (Pubitemid 30331564)
20. Leen A, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75(18):8649-8659. (Pubitemid 32768969)
21. Strowig T, et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009;206(6):1423-1434.
22. Ishikawa F, et al. Development of functional human blood and immune systems in NOD/ SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005;106(5):1565-1573. (Pubitemid 41208567)
23. Traggiai E, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304(5667):104-107. (Pubitemid 38451466)
24. Yajima M, et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008;198(5):673-682.
25. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res. 2003;63(11):2982-2989. (Pubitemid 36667173)
26. Gottschalk S, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97(4):835-843. (Pubitemid 32154261)
27. Midgley RS, Bell AI, McGeoch DJ, Rickinson AB. Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J Virol. 2003;77(21):11517-11530. (Pubitemid 37271650)
28. Görzer I, Niesters HGM, Cornelissen JJ, Puchhammer-Stöckl E. Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes. Virus Res. 2006;118(1-2):105-114.
29. Nguyen-Van D, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+ T-cell epitopes. Am J Blood Res. 2011;1(2):146-159.
30. Burrows JM, Khanna R, Sculley TB, Alpers MP, Moss DJ, Burrows SR. Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol. 1996;70(7):4829-4833. (Pubitemid 26187484)
31. Maggio EM, et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer. 2002;99(5):665-672. (Pubitemid 34538745)
32. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168(7):3195-3204. (Pubitemid 34256349)
33. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985;315(6021):672-676. (Pubitemid 15232881)
34. Mlecnik B, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429-1440.
35. Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med. 2001;193(3):405-411. (Pubitemid 32524524)
36. Paludan C, et al. Epstein-Barr nuclear antigen 1- specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169(3):1593-1603. (Pubitemid 34809208)
37. Bickham K, et al. Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J Exp Med. 2003;198(11):1653- 1663. (Pubitemid 37494158)
38. Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
39. Isaksson A, Berggren M, Ricksten A. Epstein-Barr virus U leader exon contains an internal ribosome entry site. Oncogene. 2003;22(4):572-581. (Pubitemid 36188614)
40. Aitken C, Sengupta SK, Aedes C, Moss DJ, Sculley TB. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein- Barr virus. J Gen Virol. 1994;75(pt 1):95-100. (Pubitemid 24033984)
41. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med. 2002;8(10):1098-1104. (Pubitemid 35175964)
42. Deacon EM, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993; 177(2):339-349. (Pubitemid 23117083)
43. Rooney CM, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barrvirus- related lymphoproliferation. Lancet. 1995; 345(8941):9-13.
44. Campeau E, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4(8):e6529.
45. Schmid D, Pypaert M, Münz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26(1):79-92. (Pubitemid 46109341)
46. Strowig T, et al. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood. 2010;116(20):4158-4167.
47. Gurer C, et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood. 2008;112(4):1231-1239.
48. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein- Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J Exp Med. 1996;183(3):1215-1228.
49. Subklewe M, et al. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Hum Immunol. 2005;66(9):938-949. (Pubitemid 41790529)
50. Ferlazzo G, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. 2004;172(3):1455-1462. (Pubitemid 38116788)
51. Smith CA, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4(2):73-79.
52. Spies T, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature. 1990;348(6303):744-747. (Pubitemid 120015152)
53. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog. 2009;5(6):e1000492.
54. van Dongen JJM, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4- CT98-3936. Leukemia. 2003;17(12):2257-2317. (Pubitemid 38072572)
55. Sample J, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol. 1990;64(9):4084-4092. (Pubitemid 20279813)
56. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-2739.